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A B S T R A C T   
Numerous therapeutic strategies have been developed for osteoarthritis (OA) management, including intra- 
articular (IA) injections. The ideal IA formulation should control cartilage degradation and restore synovial 
fluid viscosity. To this end, we propose to combine thermo-sensitive polymers (poloxamers) with hyaluronic acid 
(HA) to develop suitable beta-lapachone (βLap) loaded IA formulations. The development of IA formulations 
with these components entails several difficulties: low βLap solubility, unknown βLap therapeutic dose and the 
bonded commitment of easy administration and viscosupplementation. An optimized formulation was designed 
using artificial intelligence tools based on the experimental results of a wide variety of hydrogels and its ther-
apeutic capacity was evaluated on an ex vivo OA model. The formulation presented excellent rheological 
properties and significantly decreased the secretion of degradative (MMP13) and pro-inflammatory (CXCL8) 
molecules. Therefore, the developed formulation is a promising candidate for OA treatment restoring the sy-
novial fluid rheological properties while decreasing inflammation and cartilage degradation.   
1. Introduction 
Osteoarthritis (OA) is a degenerative musculoskeletal disease 
involving the full-thickness of the osteochondral unit. It is a highly 
prevalent disease affecting over 250 million people worldwide repre-
senting a huge socioeconomic burden. Moreover, the disease numbers 
keep increasing due to the ageing of the population [1,2]. Big efforts 
have been made to find strategies able to avoid or control OA progres-
sion such as local administration of stem cells, autologous blood derived 
cell concentrates, autologous chondrocyte implantation, TNF inhibitors, 
growth factors and cell derived exosomes. However, these approaches 
have shown limited clinical success and variable outcomes, restricted by 
the limited self-repair potential of hyaline cartilage and relegating cur-
rent OA treatments to those mainly devoted to alleviate the disease 
symptoms [2–7]. 
Quite recently, the crucial role of inflammation on OA progression 
has been pointed out. In fact, the level of some pro-inflammatory 
cytokines on the synovial fluid, such as IL-6, serves as a diagnostic tool of 
joint damage and can promote disease progression [8,9]. These cyto-
kines, secreted by activated synovium and cartilage stablish a chronic 
joint inflammation and a catabolic/anabolic imbalance leading to 
further cartilage degradation [10–12]. Despite the huge efforts made to 
counterbalance this altered environment, there is no therapeutic mole-
cule nowadays able to revert this pathological state making necessary to 
explore novel strategies for OA management [5]. 
New strategies to avoid disease progression should be aimed at 
modulating the above mentioned imbalance of catabolic and anabolic 
factors stablished on the disease. Beta-lapachone (βLap) is a natural 
naphtoquinone identified in vitro as a highly active molecule for the 
treatment of several types of cancer [13]. Beta-lapachone is “activable” 
by the enzyme NAD(P)H dehydrogenase [quinone] 1 (NQO1) leading to 
a futile cycle in which the molecule gets converted to its unstable hy-
droquinone form which, therefore, is oxidized to the semiquinone form 
and further oxidized to the initial quinone form [14]. This cycle causes a 
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dramatic increase in NAD+ levels and a subsequent ATP loss modifying 
cell metabolism. More recently, βLap has been pointed out as an anti- 
inflammatory and wound healing promoter molecule improving oxida-
tive stress, renal dysfunction and skeletal muscle function in renal 
injury, skeletal muscle atrophy and neuroinflammatory disease models 
[15–18]. The controversial responses to βLap treatment in healthy versus 
cancer cells can be attributed to the increased NQO1 expression levels in 
numerous tumours [14,19]. On the other hand, in non-tumoral cells, 
βLap induce heme oxygenase-1 (HO1) expression and AMP-activated 
protein kinase activation exerting cytoprotective effects [20,21]. In 
fact, βLap has been already proposed as an alternative treatment for 
multiple sclerosis, rheumatoid arthritis and osteoarthritis due to prom-
ising in vitro results [22,23]. 
Intra-articular (IA) drug administration provides several advantages 
over systemic treatments such as lower side effects, reduced cost, 
decreased systemic exposure and increased local concentration [5]. The 
administration of therapeutic molecules (mainly glucocorticoids) 
though the intra-articular route is already well-stablished for OA man-
agement. However, several limitations as a fast drug clearance from the 
joint due to the lymphatic drainage and/or the short half-life of the 
therapeutic molecules limit their efficacy. Moreover, there is a contro-
versy on while currently in use intra-articular treatments offer clinically 
relevant benefits for OA management [24]. 
The quantitative composition of the synovial fluid is modified during 
OA, characterized by an increase in volume and a decrease in viscosity. 
This change in viscosity is associated with a hyaluronic acid (HA) 
degradation and concentration reduction on the synovial fluid [25]. The 
high HA concentration is essential for the synovial fluid normal function 
and lubricating properties, a decrease in concentration causes progres-
sive joint degeneration and limit patient mobility [26]. These changes in 
synovial fluid properties could be compensated by the intra-articular 
injection of HA for viscosupplementation purposes. In this sense, the 
administration of HA through intra-articular route is already included in 
most of the OA management clinical guidelines [27]. 
The main goal of the present work is to develop βLap loaded intra- 
articular formulations able to increase the drug residence time on the 
joint and simultaneously serve as viscosupplementation systems. 
Despite the βLap therapeutic capacity, its low solubility limits the clin-
ical use and makes necessary the use of different excipients. Micelle- 
forming block copolymers as some poloxamers (Poly(ethylene oxide)- 
Poly(propylene oxide)- Poly(ethylene oxide)) allow for developing 
thermo-sensitive hydrogels in which hydrophobic molecules are incor-
porated in the micelles core increasing its solubility [28–30]. Taking 
advantage of these properties we propose to combine different polox-
amers with naturally derived HA to obtain thermo-sensitive hydrogels 
for local delivery of βLap. Injectable hydrogels present several advan-
tages for intra-articular administration [27] but their development re-
quires the understanding of complex polymeric interactions. To obtain 
optimized hydrogel formulations with the required properties in terms 
of thermosensitivity and drug solubility we took advantage of Artificial 
Intelligence tools. Optimized formulations were physiochemically 
evaluated in vitro and their therapeutic activity was evaluated on an ex 
vivo OA model. 
2. Materials and methods 
2.1. Materials 
β-Lapachone (batch L503; 3,4-dihydro-2,2-dimethyl-2H-naphthol- 
[1,2-b]pyran-5,6-dione; C15H14O3; Mw 242.3) was kindly provided 
by Laboratorio Farmacêutico do Estado de Pernambuco, LAFEPE with a 
99.9% purity estimated by DSC and HPLC. Pluronic F123® (PF123) was 
acquired from BASF and Pluronic F127® (PF127) was purchased from 
Sigma–Aldrich. 
2.2. Production and purification of microbial hyaluronic acid 
Hyaluronic acid (HA) was produced by fermentation of the bacte-
rium Streptococcus equi subsp. zooepidemicus ATCC 35246 on low-cost 
medium based on marine peptones according to the procedure 
described in [31]. Briefly, 18 h-cultures of S. zooepidemicus were run on a 
2 L-biorreactor (with a working volume of 1.8 L) at 37 ◦C, 500 rpm of 
agitation, without aeration, and pH controlled with sterile solutions of 
NaOH and HCl (both 5 M) at 6.7. The nutritive broth was composed by 
glucose, mineral salts and peptones obtained from small-spotted cat-
shark (Scyliorhinus canicula) viscera as source of organic nitrogen. At the 
end of the fermentation, bacterial biomasses were precipitated after 
mixing SDS with post-incubated medium for 10 min and its subsequent 
centrifugation at 13000 g for 30 min. HA was isolated from the corre-
spondent supernatant by a combination of chemical treatment and 
membrane purification [32,33]. 
Thus, this supernatant was treated with a hydroalcoholic-alkaline- 
saline solution (0.5 M NaOH, 1.02 volumes of EtOH and 2.5 g/L of 
NaCl) for 1–2 h for the selective precipitation of HA at 4 ◦C. The impure 
HA recovered after centrifugation (13000 g/30 min/4 ◦C) was redis-
solved in water, neutralized with 6 M HCl and centrifuged again (12000 
g/30 min/4 ◦C). Then, HA clarified supernatant was purified by ultra-
filtration using a membrane of 300 kDa MWCO (spiral polyethersulfone, 
0.56 m2, Prep/Scale-TFF, Millipore Corporation, USA) employing a first 
step of concentration (by 2-folds) and a subsequent stage of diafiltration, 
applying 6 diavolumes of distilled water for the elimination of low 
proteins and peptides. The final HA purity in relation to proteins was 
higher than 98%. HA molecular weight (Mw) was determined as pre-
viously described by gel permeation chromatography [34] indicating a 
biopolymer size of 1.54 ± 0.16 MDa (PDI 1.25). 
2.3. Preparation and physicochemical characterization of hydrogels 
2.3.1. Preparation of hydrogels 
Poloxamers (PF127 or PF123) were first dissolved at variable con-
centrations in ultrapure water (MilliQ) using ice-cold water and stored 
overnight at 4 ◦C. Isolated hyaluronic acid was incorporated into 
poloxamer solutions (PF127 or PF123) at the proportions required to 
achieve the desired concentrations showed in Supplementary Table 1. 
Solutions were continuously stirred (500 rpm) until complete 
dissolution. 
2.3.2. Drug solubility assessments 
An excess of βLap was added to the polymeric solutions and systems 
were sonicated for 15 min and kept under magnetic stirring for 7 days 
protected from light. After this period, solutions were filtered through 
0.45 μm Nylon filters (GE Healthcare Europe GmBH) to remove not 
solubilized βLap. Filtered systems were accurately diluted with a 50:50 
ethanol:water solution and the drug concentration was determined by 
spectrophotometry at 258 nm (Agilent Technologies 8453) using an 
adequate calibration curve. 
2.3.3. Rheological properties 
The rheological properties of the systems were evaluated, using a 
stress-controlled rheometer (AR1000N Rheometer, TA Instruments). A 
temperature ramp from 15 to 40 ◦C at 2 ◦C/min with an oscillatory stress 
of 0.1 Pa at 5 rad/s was carried out recording the storage and elastic 
moduli. In addition, samples were subjected to a frequency sweep with a 
rotation speed from 0.5 to 50 rad/s at 25 ◦C and 37 ◦C. Through the 
rheological characterization, the complex viscosity at 25 ◦C and 37 ◦C 
and gelling temperature were obtained. 
2.4. Artificial intelligence tools 
The experimental databases generated were analyzed using two 
artificial intelligence tools: FormRules® v3.31 and INForm® v4.11 
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(Intelligensys Ltd., 2008). FormRules® is a software that combines two 
AI technologies, artificial neural networks and fuzzy logic. It allows the 
database modelling and the generation of “IF… THEN” rules to generate 
knowledge about the effect of the different process variables on the 
characteristics of the drug delivery systems. 
On the other hand, INForm® combines artificial neural networks 
with genetic algorithms, which allows to carry out an optimization 
procedure, that is, to select the most appropriate combination of vari-
ables capable of obtaining a delivery system with the desired 
characteristics. 
The modelling was carried out using the conditions indicated in 
Table 1 employing the entire data set to obtain the model using neu-
rofuzzy logic (FormRules®) and with the data split into two groups; one 
for network training (training data = 40 conditions) and one for error 
evaluation (test data = 5 conditions) when modelled using INForm®. 
The predictability of the models was evaluated using the determi-
nation coefficient R2 (Eq. (1)) and the analysis of variance (ANOVA) 
which allows to estimate the predictability and accuracy of the models, 
respectively. 








)2 (1)  
where yi is the experimental value, ŷiis the predicted value and yi is the 
predicted average value. 
The higher the value of R2, the better the predictability of the model 
is. Values between 70 and 99.9% are indicative of good predictability 
[35]. 
2.5. Drug delivery profiles 
The evaluation of the βLap release profile from the systems was 
carried out using vertical Franz diffusion cells. Drug-containing formu-
lations (3 mL) were placed in the donor compartment and 6 mL of 
phosphate buffer pH 7.4 were used in the receptor compartment. Both 
compartments were separated by a 7000 Da pore size membrane 
(Medicell International Ltd). This pore diameter allows the drug to 
diffuse, while prevents the passage of the polymeric components of the 
gels. At pre-set time points media samples were removed from the re-
ceptor chamber and replaced by fresh media. The amount of the released 
drug was determined by UV–Visible spectrophotometry as described 
above. 
2.6. Biocompatibility of extracted hyaluronic acid 
The biocompatibility of poloxamers and hyaluronic acid has been 
already extensively reported [36,37]. However, to ensure the hyaluronic 
acid produced in this work is not toxic, cell viability was evaluated for 
cells treated with our HA. Murine fibroblasts BALB/3 T3 clone A31 
(ATCC® CCL-163™) were cultured in DMEM/F12 HAM medium 
(Sigma) supplemented with 10% foetal bovine serum (Hyclone) and 1% 
penicillin/streptomycin (ThermoScientific). Cells were seeded on 96- 
well plates at 25,000 cells/well and allowed to attach for 24 h. On the 
next day cells were incubated with hyaluronic acid at variable concen-
trations (25–200 μg/mL) for 24 h. Cell viability was assessed by means 
of a WST-1 assay (Roche) following manufacturer's instructions. Un-
treated cells served as 100% cell viability. 
2.7. Evaluation of βLap anti-inflammatory activity 
The potential anti-inflammatory effect of βLap was initially evalu-
ated on LPS-stimulated macrophages. Murine macrophages Raw 264.7 
(ATCC® CRL-2278) were cultured in DMEM/F12 HAM medium (Sigma) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/ 
streptomycin (ThermoScientific). Cells were cultured in 75 cm2 vented 
flasks at 37 ◦C with 5% CO2 and 90% relative humidity. Cell culture 
medium was changed every 2 days and cells were passaged when 
reaching 70% confluency. Macrophages were seeded in 24-well plates at 
a density of 100,000 cells per well, allowed to attach for 4 h and after-
wards, stimulated with lipopolysaccharide (LPS) (Sigma) at 100 ng/mL. 
After 24 h, stimulation media was removed. Cell monolayers were 
washed with DPBS and treated with variable concentrations of βLap 
(1–4.5 μM) or control for 24 h, media was then collected, and cell 
cytotoxicity evaluated by a commercial LDH quantification kit (Roche). 
Positive control was obtained by lysing the cells according to manu-
facturer's instructions. The cytocompatibility of blank and βLap-loaded 
optimized formulations was also evaluated. Anti-inflammatory activity 
was analyzed by quantifying the secretion of the pro-inflammatory 
molecules prostaglandin E2 (PGE2) and tumor necrosis alpha (TNF-α). 
PGE2 concentration was evaluated by a competitive EIA following 
manufacturer's instructions (Ann Arbour) and TNF-α through a com-
mercial ELISA (Sigma-Aldrich). Values are expressed as percentage of 
cytotoxicity with respect to positive control or percentage of decreased 
PGE2 and TNF-α secretion with respect to LPS-stimulated untreated cells 
and their corresponding standard deviations. 
βLap anti-inflammatory activity was also evaluated on LPS stimu-
lated OA cartilage explants. Tissues were obtained from OA patients 
undergoing total knee replacement after patients consent according to 
Ethics Committee approval (CEIC Galicia 2015/029). Immediately after 
surgery, samples were placed on sterile saline solution. Cartilage was 
washed twice with DPBS supplemented with 1% penicillin/strepto-
mycin amphotericin (Gibco) and 6-mm tissue biopsies were obtained 
using sterile punches. Samples were washed again with supplemented 
DPBS and placed on 24-well plates containing 0.5 mL of Dulbecco's 
modified eagle's medium (DMEM) supplemented with 2% fetal bovine 
serum and 1% penicillin/streptomycin. Cartilage explants were allowed 
to settle for 48 h. Afterwards, media was removed and explants were 
treated with LPS at 100 ng/mL with or without βLap at variable con-
centrations (0–3 μM) or dexamethasone (2 μM) for 48 h. Then, cell 
culture supernatants were collected to evaluate PGE2 secretion as pre-
viously described. 
2.8. Therapeutic activity evaluation of optimized formulations 
To mimic the disease environment, an ex vivo OA model was stab-
lished by co-culturing human cartilage and synovium explants. Tissues 
were obtained as previously described and cartilage explants treated as 
above mentioned. Synovium was washed twice with supplemented 
DPBS and any excess of fat tissue was removed. Samples were washed 
Table 1 
Parameters used to model the experimental databases.  
FormRules® v3.31 INForm® v4.11  
Ridge regression factor 1 e− 6 Momentum 0.80 
Number of set densities 2 Learning rate 0.70 
Set densities 2 and 3 Target iteractions 1000 
Statistical fitness criteria: structural 
risk 
Target MS error 0.0001 
Minimisation (structural risk 
minimization) 
Random seed 10,000 
C1 > 0.680; C2 = 4.80 Smart stop Enabled 
Maximum inputs per submodel 4 Network structure  
Maximum nodes per input 15 Number of inputs 2 
Adapt nodes TRUE Number of hidden 
layers 
1  
Hidden layer 1 
Number of nodes 2 
Transfer type function Asymmetric 
sigmoid 
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again and placed on supplemented media. Cartilage and synovium 
samples were allowed to settle for 24 h using standard culture conditions 
(37 ◦C and 5% CO2) and then combined using cell culture inserts (8 μm 
pore size; Corning). Synovium was placed on the upper compartment 
while cartilage was placed on the bottom. This co-culture was accli-
mated for 48 h and then media was removed and co-cultures were 
treated for additional 48 h with βLap (2 μM) or βLap loaded optimized 
formulation with equivalent drug concentration. Dexamethasone (2 
μM), clinically used to treat OA, was selected as control. Unstimulated 
co-cultures and mono cultures were also analyzed. After 48 h, media 
supernatant was collected and used to assess the secretion of pro- 
inflammatory and ECM degradative mediators. The secretion of IL-13, 
IL-6, IL-8, MMP13 and TNF-α was studied using multiplex immuno-
assay kits (R&D Systems) according to the manufacturer's instructions. 
Samples were diluted 1:1 in assay buffer and loaded into a 96-well plate, 
after which magnetic bead suspensions, detection antibodies, and 
streptavidin-phycoerythrin were added to the samples. The plate was 
then loaded into a MAGPIX system (Luminex) and analyte concentra-
tions were obtained using the correspondent calibration curve. Co- 
culture samples not treated with any of the therapeutic molecules, 
cartilage explants treated with LPS (100 ng/mL) for 48 h and cartilage 
explants without any treatment served as controls to evaluate the 
generated OA-like environment. 
2.9. Statistical analysis 
Experimental values are represented as mean ± standard deviation. 
Experiments were run in quadruplicate unless otherwise stated. One- 
way ANOVA following HSD Tukey's post hoc (IBM SPSS Statistics 26) 
was performed to detect statistical differences between treatments with 
p-values lower than 0.05 considered as statistically significant. 
3. Results and discussion 
3.1. Design of optimized formulations 
The design of intra-articular formulations aims to obtain systems 
with suitable performance in terms of easy administration, long resi-
dence time in the diseased joint and effective therapeutic molecule 
release. Thermosensitive hydrogels are ideal systems as drug carriers for 
intra-articular administration as their administration by injection is 
minimally invasive, and they can gel at body temperature, giving rise to 
controlled release drug delivery systems that maximize drug local effects 
[38]. However, most of the anti-inflammatory drugs currently used for 
OA treatment, also βLap, are characterized by low aqueous solubility, 
entailing a challenge for their inclusion in hydrophilic polymeric net-
works. Poloxamers are able to generate themosensitive micelle-based 
hydrogels that meet the requirements for intra-articular administra-
tion of these drugs, increasing their solubility by their incorporation into 
the hydrophobic micelles core. 
Viscosupplementation is a widely used strategy in OA management 
with good clinical outcomes. To this end, hyaluronic acid is mainly the 
polymer used owing to its major role in joint lubrication. 
In an attempt to combine the advantages of local drug delivery 
platforms (thermosensitive micelle-based hydrogels) with viscosupple-
mentation (hyaluronic acid), binary systems (poloxamer+HA) were 
developed. The design of suitable systems for OA treatment requires a 
deep knowledge of both polymer-polymer interactions and critical pa-
rameters conditioning the developed systems properties. Innovative 
technologies as artificial intelligence tools can speed up the challenging 
goal of formulation optimization. 
In this work, the performance of PF123 +HA and PF127 +HA binary 
systems at variable polymer concentrations was evaluated in terms of 
drug solubility enhancement and rheological behaviour (Supplementary 
Table 1). 
The range of HA concentrations (0–15 mg/mL) was selected based on 
the marketed HA formulations for viscosupplementation (8–15 mg/mL). 
Three formulation parameters (model outputs) were selected as crucial 
to assess system performance, solubilized βLap, viscosity at 25 ◦C (η25) 
and viscosity at 37 ◦C (η37). The first factor is important to ensure 
adequate drug loading while hydrogel viscosities are used to evaluate 
hydrogel injectability (η25) and viscosupplementation effect (η37). 
Table 2 shows the FormRules® results, including the main inputs that 
explain the variability of each property (output) together with the pa-
rameters that guarantee the quality of the models. FormRules® suc-
cessfully modelled the three parameters studied with R2 values over 
70%, indicative of good predictabilities. Moreover, the ANOVA 
computed f values were higher than the f critical values in all cases 
indicative of not statistically significant differences between experi-
mental and predicted values (p < 0.01). Therefore, the three models 
presented excellent predictability and accuracy and can be used to 
explain the composition effect on the systems performance. 
According to the models, βLap loading capacity is determined by the 
interaction between the type of poloxamer and its concentration. As 
depicted on the 3D plot of this output (Fig. 1A and B) and the “IF-THEN” 
rules (Supplementary Table 2), a higher drug solubility was observed for 
hydrogels containing PF123. This polymer has a greater hydrophobic/ 
hydrophilic (PPO/PEO) ratio and lower critical micelle concentrations 
(CMC) than PF127. These characteristics conferee PF123 a higher sol-
ubilization efficiency for medium hydrophobic drugs when compared to 
PF127 despite its lower molecular weight [39]. This behaviour is 
confirmed by our experimental data for the highly hydrophobic drug 
βLap. 
The effect of the composition on hydrogel rheological properties was 
clearly dependent on the temperature (Fig. 1C–F). At 25 ◦C the systems 
viscosity was controlled by the concentration of hyaluronic acid while at 
37 ◦C this feature was affected by the type of poloxamer used and its 
concentration. This performance is explained by the sol to gel thermo-
sensitive transition attribute of poloxamer solutions. These polymers 
behave as solutions under the transition temperature and as semi-solid 
systems above this temperature due to the ordered packing of micelles 
[40]. Despite PF123 presents lower CMC, its low molecular weight 
hinders the sol to gel transition of the hydrogels at the concentrations 
used on this work. Therefore, only hydrogels prepared with PF127 at 
concentrations higher than 10% were able to undergo this shift and 
presented a clear increase in viscosity as shown on the 3D plot 
(Fig. 1D–F). On the other hand, the variations in viscosity at 25 ◦C were 
mainly explained by the incorporation of HA to the formulation. An 
increase in hyaluronic acid concentration above 9 mg/mL led to a 
concentration dependent enhancement in system viscosity reaching the 
maximum value at the highest HA concentration, 15 mg/mL 
(Fig. 1C–D). 
Once the influence of the hydrogel's composition on the above 
mentioned parameters was stablished, the next step is to select an 
optimized composition able to fulfil the requirements of IA adminis-
tration for viscosupplementation and drug delivery. PF127 was selected 
as the thermosensitive polymer to be used based on the above 
mentioned rheological characteristics. The following attributes were 
selected as desirable η25 < 2 Pa.s, and solubilized βLap >100 μg/mL and 
Table 2 
Inputs selected by FormRules® to explain the outputs variability and parameters 
to assess the quality of the generated models; R2 (predictability) and ANOVA 
(accuracy) (d.f. stands for degrees of freedom).  
Outputs Inputs from 
FormRules® 
R2 d.f. Calculated f- 
ratio 
f critical for 
(p < 0.01) 
Solubilized 
βLap 
PF × [PF]  85.61 8 and 
26  
13.39  3.29 
η25 [HA]  89.07 3 and 
41  
103.29  4.30 
η37 PF × [PF]  72.93 6 and 
35  
15.71  3.37  
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the optimization was performed using the software INForm®. The 
composition selected by the model through genetic algorithms was 15% 
PF127 and 6.37 mg/mL HA. Theoretically, according to the model, this 
composition should give systems with η25 = 1.24 Pa.s and solubilized 
βLap = 83.97 μg/mL. 
3.2. Performance of optimized system: physicochemical properties 
Optimized formulations containing PF127 and HA were prepared 
and characterized as previously described. Hyaluronic acid solutions at 
the same proportion as in the optimized formulation (6.37 mg/mL) were 
also prepared and characterized in terms of rheological properties to 
serve as control. The experimental characteristics of the optimal 
formulation (solubilized βLap = 85.25 ± 20.64 μg/mL; η25 = 1.11 ±
0.01 Pa.s) were remarkably close to those predicted by the model, 
confirming its validity. βLap loaded optimized systems presented the 
characteristic orange colour of the drug (Supplementary Fig. 1). The 
combination of PF127 with the hyaluronic acid produced on this work 
(1.54 × 106 Da) provided a positive effect on the viscoelastic properties 
of the obtained systems. Formulations exhibited at 37 ◦C a non- 
newtonian shear thinning behaviour, similar to that reported for 
human synovial fluid (Fig. 2A) [41]. The values of elastic (G') and 
viscous (G") moduli at variable frequencies showed a viscous behaviour 
over the entire range of frequencies for HA alone with a viscous modulus 
higher than the elastic modulus (Fig. 2B). On the other hand, when 
PF127 is added, a gel behaviour is observed, with the elastic modulus 
being higher than the viscous modulus throughout the range of fre-
quencies. The sol to gel transition of the biphasic system is clearly 
observed on Fig. 2C behaving as a viscous solution at low temperatures 
and as a gel after a temperature threshold of 26.45 ± 1.17 ◦C. This 
Fig. 1. 3D plots of the obtained models for hydrogels prepared with PF123 (A, C, E) or PF127 (B, D, F) of the analyzed parameters; drug solubility (A&B), viscosity at 
25 ◦C (B&D) and viscosity at 37 ◦C (E&F). 
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property allows for an easy administration at room temperature while 
acting as a good viscosuppplementator after injection (37 ◦C). In fact, 
PF127 + HA formulation showed a viscosity at 37 ◦C and low shear rate 
(179.3 ± 41.9 Pa.s) superior to the already commercialized solutions 
using HA of low molecular weight, presenting excellent viscosupple-
mentation capacity [41]. 
3.3. Drug delivery profiles of optimized systems 
Optimized binary system showed a linear drug release profile 
(Fig. 3), fitting a zero-order release kinetic, characteristic of depot sys-
tems. The obtained release constant was 0.45 μgβLap/h (r2 = 0.9996) 
ensuring the βLap sustained release. IA depot systems have been re-
ported to significantly increase therapeutic molecules half-life in the 
affected joint endorsing sustained drug distribution and allowing to use 
lower drug doses and longer dosing intervals [42]. 
3.4. Biocompatibility of extracted hyaluronic acid 
To ensure the extracted hyaluronic acid did not promote undesirable 
effects on cells, fibroblast monolayers were treated with variable con-
centrations of HA (25–200 μg/mL). Fig. 4 shows the cell metabolic ac-
tivity after 24 h of treatment. No cytotoxic effect was observed for any of 
the concentrations tested with values similar to those of non-treated 
cells (Control -) in agreement with the already well-known high 
biocompatibility of hyaluronic acid [37]. 
3.5. Evaluation of βLap anti-inflammatory activity 
Recent experiments have suggested the anti-inflammatory capacity 
of βLap. However, its anti-inflammatory effects on chondrocytes has not 
been elucidated yet. In this work, we have evaluated the anti- 
inflammatory capacity of βLap on both LPS-stimulated macrophages 
and OA cartilage explants to select an appropriated βLap therapeutic 
concentration. The experimental data (Fig. 5A–B) showed a dose- 
Fig. 2. Rheological properties of the optimized formulation (HA + PF127) and hyaluronic acid solution at equivalent concentration.  
Fig. 3. Drug release profiles of optimized systems in PBS pH 7.4.  Fig. 4. Fibroblast metabolic activity after 24 h of treatment with HA solutions.  
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dependent decrease in TNF-α and PGE2 secretion when pro- 
inflammatory macrophages were treated with βLap solutions. The 
dose-dependent decrease in TNF-α secretion after βLap treatment has 
been previously reported on LPS stimulated microglia [18]. Moreover, 
in agreement with studies using other cell types the treatment with βLap 
at concentrations over 3 μM led to cell death (Supplementary Fig. 2) 
[43]. Also, no cytotoxic effects were observed for blank and βLap loaded 
optimized formulations (Supplementary Fig. 2). 
Interestingly, stimulated explants did not show a dose-dependent 
response to βLap. The addition of βLap significantly decreased the 
secretion of PGE2, but no differences were noted between the concen-
trations tested (Fig. 5C). This decrease in the pro-inflammatory mediator 
secretion was similar to that observed for Dexamethasone control 
reaching levels close to non-stimulated explants (data not shown). 
The anti-inflammatory effects exerted by βLap have been associated 
to the inhibition of NF-κB activation. TLRs are sensors of the innate 
immune system recognizing pathogens and triggering the host defense. 
The activation of the transcription factor NF-κB is the end step of toll-like 
receptors (TLRs) signalling pathways and controls the expression of a 
wide variety of genes encoding pro-inflammatory molecules. Therefore, 
βLap could modulate cytokine gene expression by suppressing TLR sig-
nalling pathways [44–46]. Other authors have pointed out the ability of 
βLap to not only inhibit NF-κB activation but also inhibit the phos-
phorylation of several types of mitogen-activated protein kinases 
(MAPKs) and AKT, promoting an anti-inflammatory effect involving 
several pathways [18,47]. 
3.6. Therapeutic activity of optimized formulations in a OA model 
Based on the βLap activity (comparable to Dexamethasone), the 
systems release profile and the reported synovial fluid volume, opti-
mized formulations were loaded with βLap at 70 μM (16 μg/mL). The 
activity of these systems was evaluated on the developed ex vivo OA 
model. To elucidate whether this co-culture efficiently led to an OA 
mimetic environment we evaluated the secretion of several cytokines 
and matrix degradative enzymes (Fig. 6A). 
TLRs play an important role on cartilage inflammation during OA 
progression. Their activation by danger-associated molecules leads to 
the secretion of pro-inflammatory cytokines such as TNF-α and IL-6 
[48]. Moreover, LPS is a well-known TLR4 agonist. In this way, the 
stimulation of cartilage explants with LPS significantly increased the 
secretion of all the analyzed cytokines (TNF-α, IL-6, CXCL8 and IL-13) 
(Fig. 6A). On the other hand, the co-culture of cartilage explants with 
synovial tissue also led to increased levels of TNF-α, IL-6, CXCL8 and IL- 
13 on the cell culture supernatant when compared to unstimulated ex-
plants similarly to LPS stimulation except for IL-6. Interestingly, the co- 
culture set-up also allowed for a statistically significant increase in the 
secretion of MMP13, a key degradative enzyme during OA progression. 
These findings suggest the developed synovium/cartilage co-culture 
achieved a more OA mimetic environment. These results are in agree-
ment with other authors [49] who have reported increases in MMP-3 
and IL-6 at long times in co-cultures of osteochondral explants and sy-
novial membrane with respect to osteochondral explants cultured alone. 
MMP13 is a matrix degradative enzyme secreted by chondrocytes, 
implicated in collagen and proteoglycan degradation. MMP13 is 
considered the most important collagen degradative enzyme in the 
Fig. 5. A) TNF-α secretion and B) PGE2 secretion of LPS-stimulated macrophages after 24 h treatment with variable βLap concentration. C) PGE2 secretion of LPS- 
stimulated OA cartilage explants after 72 h treatment with Dexamethasone 1 μM or variable βLap concentrations. $ denotes statistical significance (p < 0.05) when 
compared to stimulated cells or explants without treatment. * denotes statistical significance (p < 0.05) when compared to 1 μM βLap. 
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cartilage and one of the main drivers and inductors of the OA degra-
dative process. In fact, different strategies to control OA are being 
focused on inhibiting MMP13 [50]. Interestingly, βLap alone or loaded 
in the optimized formulation was able to significantly decrease the 
secretion of MMP13 (Fig. 6B). The capacity of βLap to decrease MMP 
expression has been already described in interleukin-1 stimulated pri-
mary chondrocytes [22]. Moreover, the treatment with the optimized 
formulations was able to significantly decrease the secretion of CXCL8 to 
a similar extend as Dexamethasone. Despite co-cultured explants treated 
with βLap alone showed lower TNF-α and MMP-13 secretion than those 
treated with the βLap loaded optimized formulation the differences 
between both treatments were not statistically significant (p-values 
>0.67). 
The results suggest the combination of HA and βLap could lead not 
only to an increase in the synovial fluid viscosity but also to a decrease in 
the degradation rate of both, injected and patient's HA, due to the anti- 
inflammatory action of βLap that would control the pro-inflammatory 
environment of the joint [42]. Therefore, the developed formulation 
could increase the half-life in the affected joint of both βLap and injected 
HA characterized by a short half-life of about 13 h [51]. 
4. Conclusions 
The use of artificial intelligence tools has allowed to stablish the 
suitable composition of Pluronic+HA hydrogels for IA. The optimized 
formulation postulated as adequate for the treatment of OA was 
injectable and achieved adequate viscosupplementation while ensured 
βLap controlled release. 
The treatment of M1 macrophages and LPS-stimulated cartilage ex-
plants with βLap shows the drug ability to reset the inflammatory 
environment towards a less pro-inflammatory profile. The use of an ex 
vivo synovium/cartilage co-culture set up allowed for a more OA-like 
environment, suitable to test the developed formulations. 
The optimized formulation is a promising candidate for the 
treatment of OA, as it can restore the rheological properties of synovial 
fluid improving joint function while decreasing inflammation and the 
established cartilage degradative environment. 
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Fig. 6. A) Cytokines (TNF-α, IL-6, CXCL8 and IL-13) and 
matrix metalloproteases s (MMP13) secretion of OA carti-
lage explants cultured for 48 h without treatment (ex-
plants), treated with LPS at 100 ng/mL (Explants + LPS) or 
co-cultured with patient matched synovial tissue (Co-cul-
ture). B) Cytokines and MMPs secretion of OA cartilage and 
synovial tissue co-cultured for 48 h and treated with 
Dexamethasone (control drug), βLap or βLap loaded opti-
mized formulation. $ denotes statistical significance (p <
0.05) when compared to explants without treatment (6A) or 
untreated co-culture (6B). * denotes statistical significance 
(p < 0.05) when compared to Explants treated with LPS.   
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Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.msec.2021.112254. 
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